Fatty liver disease medication may have no effect

A new randomised, prospective trial has shown that orlistat, a commonly prescribed inhibitor of fat absorption, does not help patients with fatty liver disease (FLD) lose weight, nor does it improve their liver enzymes or insulin resistance. These findings are in the January issue of Hepatology, a journal published by John Wiley and Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience...

Read the whole article on

More from